New
HealthMore in Health→
Indonesian Court Rejects 'Patent Evergreening' in Win for Medicine Access
Key Takeaways
- A recent Indonesian court ruling rejected the pharmaceutical industry's use of 'patent evergreening,' according to STAT News.
- Patient advocates say the decision sends an important message to other countries considering similar challenges.
- Patent evergreening refers to strategies that extend market exclusivity on medicines beyond core patent terms.
- The ruling is seen as significant for access to affordable medicines, particularly in lower- and middle-income markets.
DE
DT Editorial Team··via statnews.com